<ul>
<li>3 只生物科技股票可能受益於專利懸崖</li>
</ul>
<p>CRISPR Therapeutics AG (NASDAQ:CRSP - 免費報告) - Brookline Capital Markets 的股票研究分析師在 5 月 5 日星期二發佈的研究報告中下調了對 CRISPR Therapeutics 2028 財年的每股收益預期。Brookline Capital Markets 分析師 L. Cann 現在預測該公司將發佈每股收益 6.91 美元，低於之前預測的 7.44 美元。CRISPR Therapeutics 當前全年的共識預期為每股虧損 4.93 美元。</p>
<p>獲取 <strong>CRISPR Therapeutics</strong> 的提醒：</p>
<p>CRISPR Therapeutics (NASDAQ:CRSP - 獲取免費報告) 最近在 5 月 5 日星期二發佈了季度財報。該公司報告季度每股虧損 1.28 美元，低於分析師共識預期的每股虧損 1.22 美元，差額為 0.06 美元。該季度的收入為 146 萬美元，而分析師預期為 606 萬美元。CRISPR Therapeutics 的股本回報率為負 25.53%，淨利潤率為負 13,856.54%。與去年同期相比，該季度的收入增長了 68.6%。在去年同期，該公司每股虧損 1.58 美元。</p>
<ul>
<li>CRISPR Therapeutics 在財報後上漲，管線希望增加</li>
</ul>
<p>其他一些券商最近也對 CRSP 發表了評論。Piper Sandler 在 3 月 17 日星期二的研究報告中重申了 “增持” 評級，並將 CRISPR Therapeutics 的目標價從 105.00 美元上調至 110.00 美元。美國銀行在 1 月 22 日星期四的研究報告中將 CRISPR Therapeutics 的目標價從 90.00 美元下調至 89.00 美元，並對該股票給予 “買入” 評級。Citizens Jmp 在 1 月 30 日星期五的研究報告中將 CRISPR Therapeutics 的目標價從 86.00 美元下調至 80.00 美元，並對該股票給予 “市場表現優於大盤” 評級。TD Cowen 在 2 月 13 日星期五的研究報告中將 CRISPR Therapeutics 的目標價從 40.00 美元上調至 45.00 美元，並給予該股票 “持有” 評級。最後，摩根士丹利在 2 月 17 日星期二的研究報告中重申了 “減持” 評級，並將 CRISPR Therapeutics 的目標價設定為 33.00 美元。一位投資分析師對該股票給予了強烈買入評級，十位給予買入評級，六位給予持有評級，兩位給予賣出評級。根據 MarketBeat 的數據，CRISPR Therapeutics 目前的共識評級為 “適度買入”，共識目標價為 64.53 美元。</p>
<p><strong>閲讀我們關於 CRSP 的最新研究報告</strong></p>
<h2>CRISPR Therapeutics 價格表現</h2>
<ul>
<li>CRSPR 股票可能準備兑現其巨大的承諾</li>
</ul>
<p>CRSP 股票在星期三開盤價為 52.38 美元。該股票的 50 日移動平均線為 52.41 美元，200 日移動平均線為 54.60 美元。該股票的市值為 50.5 億美元，市盈率為 -8.42，貝塔值為 1.74。CRISPR Therapeutics 的 12 個月低點為 33.03 美元，12 個月高點為 78.48 美元。</p>
<h2>CRISPR Therapeutics 的內部交易</h2>
<p>在相關消息中，首席法律顧問 James R. Kasinger 於 3 月 23 日星期一出售了 3,182 股公司的股票。股票以平均價格 46.78 美元出售，總價值為 148,853.96 美元。出售完成後，首席法律顧問直接持有公司 94,308 股股票，價值 4,411,728.24 美元。此次交易使其持股減少了 3.26%。該出售在與證券交易委員會的備案中披露，相關信息可通過此鏈接獲取。此外，首席執行官 Samarth Kulkarni 於 3 月 23 日星期一出售了 10,020 股公司的股票。股票以平均價格 46.78 美元出售，總價值為 468,735.60 美元。出售完成後，首席執行官直接持有公司 255,501 股股票，價值約 11,952,336.78 美元。這代表其持股減少了 3.77%。該出售的 SEC 備案提供了更多信息。在過去的九十天裏，內部人士已出售 51,828 股公司股票，價值 2,578,097 美元。當前 4.10% 的股票由內部人士持有。</p>
<h2>對 CRISPR Therapeutics 的對沖基金看法</h2>
<p>機構投資者最近對該股票的持倉進行了調整。Mcguire Capital Advisors Inc. 在第四季度購買了價值約 25,000 美元的 CRISPR Therapeutics 新頭寸。Ramirez Asset Management Inc. 在第四季度購買了價值約 26,000 美元的 CRISPR Therapeutics 新頭寸。Rothschild Investment LLC 在第四季度將其在 CRISPR Therapeutics 的持股增加了 836.7%。Rothschild Investment LLC 現在擁有 562 股公司股票，價值 29,000 美元，此前在上個季度購買了額外的 502 股。Thurston Springer Miller Herd &amp; Titak Inc. 在第四季度將其在 CRISPR Therapeutics 的持股增加了 196.9%。Thurston Springer Miller Herd &amp; Titak Inc. 現在擁有 576 股公司股票，價值 30,000 美元，此前在上個季度購買了額外的 382 股。最後，Optiver Holding B.V. 在第三季度將其在 CRISPR Therapeutics 的持股增加了 71.4%。Optiver Holding B.V. 現在擁有 504 股公司股票，價值 33,000 美元，此前在上個季度購買了額外的 210 股。69.20% 的股票由機構投資者持有。</p>
<h2>關於 CRISPR Therapeutics</h2>
<p>(獲取免費報告)</p>
<p>CRISPR Therapeutics AG 是一家生物製藥公司，專注於基於 CRISPR/Cas9 平台的基因編輯療法的開發。該公司應用其專有技術對人類細胞中的基因進行修改，旨在為一系列嚴重疾病創造持久的治療方案。其研發工作重點包括體外和體內應用，使得能夠針對性地修正或破壞致病基因。</p>
<p>其主要項目之一是 CTX001，這是一種外源性編輯細胞療法，旨在治療鐮狀細胞病和依賴輸血的 β-地中海貧血，與 Vertex Pharmaceuticals 合作開發。</p>
<h2>進一步閲讀</h2>
<ul>
<li>五隻我們認為比 CRISPR Therapeutics 更好的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元於 CRISPR Therapeutics 嗎？</h2>
<p>在你考慮投資 CRISPR Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，而 CRISPR Therapeutics 並不在名單上。</p>
<p>雖然 CRISPR Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

CRISPR治療

基因改革 ETF - ARK

基因免疫&健康關懷 ETF - iShares

<p>CRISPR Therapeutics AG (NASDAQ:CRSP) 的 2028 財年每股收益預期從 Brookline Capital Markets 下調，從 7.44 美元降至 6.91 美元。該公司報告的季度每股收益為（1.28 美元），未達到預期，收入為 146 萬美元。分析師對該股票的評級不一，普遍評級為 “適度買入”，目標價格為 64.53 美元。近期發生了內部人士的股票出售，機構投資者正在調整其在該股票上的持倉</p>

<ul>
<li>3 Biotech Stocks That Could Benefit from the Patent Cliff</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只生物科技股票可能受益於專利懸崖</li>
</ul>
</div><p>CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Equities research analysts at Brookline Capital Markets dropped their FY2028 earnings per share estimates for CRISPR Therapeutics in a research note issued on Tuesday, May 5th. Brookline Capital Markets analyst L. Cann now forecasts that the company will post earnings of $6.91 per share for the year, down from their prior forecast of $7.44. The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($4.93) per share.</p>
<div class="lb-trans"><p>CRISPR Therapeutics AG (NASDAQ:CRSP - 免費報告) - Brookline Capital Markets 的股票研究分析師在 5 月 5 日星期二發佈的研究報告中下調了對 CRISPR Therapeutics 2028 財年的每股收益預期。Brookline Capital Markets 分析師 L. Cann 現在預測該公司將發佈每股收益 6.91 美元，低於之前預測的 7.44 美元。CRISPR Therapeutics 當前全年的共識預期為每股虧損 4.93 美元。</p>
</div><p>Get <strong>CRISPR Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>CRISPR Therapeutics</strong> 的提醒：</p>
</div><p>CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($1.28) EPS for the quarter, missing analysts' consensus estimates of ($1.22) by ($0.06). The company had revenue of $1.46 million for the quarter, compared to analyst estimates of $6.06 million. CRISPR Therapeutics had a negative return on equity of 25.53% and a negative net margin of 13,856.54%.The company's revenue for the quarter was up 68.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.58) EPS.</p>
<div class="lb-trans"><p>CRISPR Therapeutics (NASDAQ:CRSP - 獲取免費報告) 最近在 5 月 5 日星期二發佈了季度財報。該公司報告季度每股虧損 1.28 美元，低於分析師共識預期的每股虧損 1.22 美元，差額為 0.06 美元。該季度的收入為 146 萬美元，而分析師預期為 606 萬美元。CRISPR Therapeutics 的股本回報率為負 25.53%，淨利潤率為負 13,856.54%。與去年同期相比，該季度的收入增長了 68.6%。在去年同期，該公司每股虧損 1.58 美元。</p>
</div><ul>
<li>CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows</li>
</ul>
<div class="lb-trans"><ul>
<li>CRISPR Therapeutics 在財報後上漲，管線希望增加</li>
</ul>
</div><p>A number of other brokerages have also recently commented on CRSP. Piper Sandler restated an &#34;overweight&#34; rating and set a $110.00 price objective (up from $105.00) on shares of CRISPR Therapeutics in a research note on Tuesday, March 17th. Bank of America dropped their target price on CRISPR Therapeutics from $90.00 to $89.00 and set a &#34;buy&#34; rating on the stock in a research report on Thursday, January 22nd. Citizens Jmp dropped their target price on CRISPR Therapeutics from $86.00 to $80.00 and set a &#34;market outperform&#34; rating on the stock in a research report on Friday, January 30th. TD Cowen lifted their target price on CRISPR Therapeutics from $40.00 to $45.00 and gave the stock a &#34;hold&#34; rating in a research report on Friday, February 13th. Finally, Morgan Stanley reaffirmed an &#34;underweight&#34; rating and set a $33.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday, February 17th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat, CRISPR Therapeutics presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $64.53.</p>
<div class="lb-trans"><p>其他一些券商最近也對 CRSP 發表了評論。Piper Sandler 在 3 月 17 日星期二的研究報告中重申了 “增持” 評級，並將 CRISPR Therapeutics 的目標價從 105.00 美元上調至 110.00 美元。美國銀行在 1 月 22 日星期四的研究報告中將 CRISPR Therapeutics 的目標價從 90.00 美元下調至 89.00 美元，並對該股票給予 “買入” 評級。Citizens Jmp 在 1 月 30 日星期五的研究報告中將 CRISPR Therapeutics 的目標價從 86.00 美元下調至 80.00 美元，並對該股票給予 “市場表現優於大盤” 評級。TD Cowen 在 2 月 13 日星期五的研究報告中將 CRISPR Therapeutics 的目標價從 40.00 美元上調至 45.00 美元，並給予該股票 “持有” 評級。最後，摩根士丹利在 2 月 17 日星期二的研究報告中重申了 “減持” 評級，並將 CRISPR Therapeutics 的目標價設定為 33.00 美元。一位投資分析師對該股票給予了強烈買入評級，十位給予買入評級，六位給予持有評級，兩位給予賣出評級。根據 MarketBeat 的數據，CRISPR Therapeutics 目前的共識評級為 “適度買入”，共識目標價為 64.53 美元。</p>
</div><p><strong>Read Our Latest Research Report on CRSP</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 CRSP 的最新研究報告</strong></p>
</div><h2>CRISPR Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>CRISPR Therapeutics 價格表現</h2>
</div><ul>
<li>CRSPR Stock Could Be Ready to Deliver on Its Massive Promise</li>
</ul>
<div class="lb-trans"><ul>
<li>CRSPR 股票可能準備兑現其巨大的承諾</li>
</ul>
</div><p>Shares of CRSP opened at $52.38 on Wednesday. The stock's 50-day moving average is $52.41 and its two-hundred day moving average is $54.60. The stock has a market cap of $5.05 billion, a PE ratio of -8.42 and a beta of 1.74. CRISPR Therapeutics has a 12 month low of $33.03 and a 12 month high of $78.48.</p>
<div class="lb-trans"><p>CRSP 股票在星期三開盤價為 52.38 美元。該股票的 50 日移動平均線為 52.41 美元，200 日移動平均線為 54.60 美元。該股票的市值為 50.5 億美元，市盈率為 -8.42，貝塔值為 1.74。CRISPR Therapeutics 的 12 個月低點為 33.03 美元，12 個月高點為 78.48 美元。</p>
</div><h2>Insider Transactions at CRISPR Therapeutics</h2>
<div class="lb-trans"><h2>CRISPR Therapeutics 的內部交易</h2>
</div><p>In related news, General Counsel James R. Kasinger sold 3,182 shares of the business's stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $46.78, for a total value of $148,853.96. Following the completion of the sale, the general counsel directly owned 94,308 shares of the company's stock, valued at $4,411,728.24. The trade was a 3.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this link. Also, CEO Samarth Kulkarni sold 10,020 shares of the business's stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $46.78, for a total value of $468,735.60. Following the completion of the sale, the chief executive officer directly owned 255,501 shares of the company's stock, valued at approximately $11,952,336.78. This represents a 3.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 51,828 shares of company stock valued at $2,578,097. 4.10% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在相關消息中，首席法律顧問 James R. Kasinger 於 3 月 23 日星期一出售了 3,182 股公司的股票。股票以平均價格 46.78 美元出售，總價值為 148,853.96 美元。出售完成後，首席法律顧問直接持有公司 94,308 股股票，價值 4,411,728.24 美元。此次交易使其持股減少了 3.26%。該出售在與證券交易委員會的備案中披露，相關信息可通過此鏈接獲取。此外，首席執行官 Samarth Kulkarni 於 3 月 23 日星期一出售了 10,020 股公司的股票。股票以平均價格 46.78 美元出售，總價值為 468,735.60 美元。出售完成後，首席執行官直接持有公司 255,501 股股票，價值約 11,952,336.78 美元。這代表其持股減少了 3.77%。該出售的 SEC 備案提供了更多信息。在過去的九十天裏，內部人士已出售 51,828 股公司股票，價值 2,578,097 美元。當前 4.10% 的股票由內部人士持有。</p>
</div><h2>Hedge Funds Weigh In On CRISPR Therapeutics</h2>
<div class="lb-trans"><h2>對 CRISPR Therapeutics 的對沖基金看法</h2>
</div><p>Institutional investors have recently made changes to their positions in the stock. Mcguire Capital Advisors Inc. bought a new position in shares of CRISPR Therapeutics during the fourth quarter valued at approximately $25,000. Ramirez Asset Management Inc. bought a new position in shares of CRISPR Therapeutics during the fourth quarter valued at approximately $26,000. Rothschild Investment LLC grew its holdings in shares of CRISPR Therapeutics by 836.7% during the fourth quarter. Rothschild Investment LLC now owns 562 shares of the company's stock valued at $29,000 after purchasing an additional 502 shares during the last quarter. Thurston Springer Miller Herd &amp; Titak Inc. grew its holdings in shares of CRISPR Therapeutics by 196.9% during the fourth quarter. Thurston Springer Miller Herd &amp; Titak Inc. now owns 576 shares of the company's stock valued at $30,000 after purchasing an additional 382 shares during the last quarter. Finally, Optiver Holding B.V. grew its holdings in shares of CRISPR Therapeutics by 71.4% during the third quarter. Optiver Holding B.V. now owns 504 shares of the company's stock valued at $33,000 after purchasing an additional 210 shares during the last quarter. 69.20% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>機構投資者最近對該股票的持倉進行了調整。Mcguire Capital Advisors Inc. 在第四季度購買了價值約 25,000 美元的 CRISPR Therapeutics 新頭寸。Ramirez Asset Management Inc. 在第四季度購買了價值約 26,000 美元的 CRISPR Therapeutics 新頭寸。Rothschild Investment LLC 在第四季度將其在 CRISPR Therapeutics 的持股增加了 836.7%。Rothschild Investment LLC 現在擁有 562 股公司股票，價值 29,000 美元，此前在上個季度購買了額外的 502 股。Thurston Springer Miller Herd &amp; Titak Inc. 在第四季度將其在 CRISPR Therapeutics 的持股增加了 196.9%。Thurston Springer Miller Herd &amp; Titak Inc. 現在擁有 576 股公司股票，價值 30,000 美元，此前在上個季度購買了額外的 382 股。最後，Optiver Holding B.V. 在第三季度將其在 CRISPR Therapeutics 的持股增加了 71.4%。Optiver Holding B.V. 現在擁有 504 股公司股票，價值 33,000 美元，此前在上個季度購買了額外的 210 股。69.20% 的股票由機構投資者持有。</p>
</div><h2>About CRISPR Therapeutics</h2>
<div class="lb-trans"><h2>關於 CRISPR Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.</p>
<div class="lb-trans"><p>CRISPR Therapeutics AG 是一家生物製藥公司，專注於基於 CRISPR/Cas9 平台的基因編輯療法的開發。該公司應用其專有技術對人類細胞中的基因進行修改，旨在為一系列嚴重疾病創造持久的治療方案。其研發工作重點包括體外和體內應用，使得能夠針對性地修正或破壞致病基因。</p>
</div><p>Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.</p>
<div class="lb-trans"><p>其主要項目之一是 CTX001，這是一種外源性編輯細胞療法，旨在治療鐮狀細胞病和依賴輸血的 β-地中海貧血，與 Vertex Pharmaceuticals 合作開發。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than CRISPR Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比 CRISPR Therapeutics 更好的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JTUA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=CRSP"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in CRISPR Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元於 CRISPR Therapeutics 嗎？</h2>
</div><p>Before you consider CRISPR Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮投資 CRISPR Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，而 CRISPR Therapeutics 並不在名單上。</p>
</div><p>While CRISPR Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 CRISPR Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

FY2028 EPS Estimates for CRSP Decreased by Analyst

Market Beat

Invesco Nasdaq Biotechnology ETF

Wisdomtree BioRevolution Fund ETF

紐交所高增長板生物技術指數 ETF - First Trust

標普生物技術 3 倍做多 - Direxion

動態生物技術與基因組 ETF - Invesco

生物科技 ETF - VanEck Vectors

醫藥突破 ETF - ALPS

2 倍做多納斯達克生物技術 ETF - ProShares

標普生物技術 ETF - SPDR

納斯達克生物科技指數 ETF - iShares Nasdaq

Piper Sandler Cos

美國銀行

Citizens Financial

Toronto Dominion Bank

摩根士丹利

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SR I

CITIZENS FINANCIAL GROUP INC 5% DEP SHS EA REP 1/40TH NON CUM SER E

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SER H

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

分析師下調了對 CRSP 公司 2028 財年的每股收益預期